Especially in the era of novel AD biomarkers (blood-based, CSF, PET scans), AD treatments, and new definitions of Alzheimer's (Alz Association 2025) - possible to develop "preclinical AD" with just a biomarker.
Any resources for how to counsel patients in this new era would be very helpful...